Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)
- PMID: 20441604
- PMCID: PMC2888214
- DOI: 10.1186/ar2976
Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)
Abstract
BLyS and APRIL are closely related members of the TNF ligand superfamily. These cytokines individually may contribute importantly to the development and maintenance of systemic lupus erythematosus (SLE). Dillon and colleagues demonstrate that in contrast to most members of the TNF ligand superfamily, which form only homotrimers, BLyS and APRIL can complex as heterotrimers. These complexes have in vitro biological activity, and circulating levels of BLyS/APRIL heterotrimers are frequently elevated in SLE, but not rheumatoid arthritis, patients. Although the mechanism and regulation of heterotrimer formation, the interconversion (if any) between homotrimers and heterotrimers, and, indeed, the normal physiologic role for such heterotrimers remain unknown, their preferential overexpression in SLE, but not in rheumatoid arthritis, raises the possibility that such heterotrimers may be playing a contributory role in SLE.
Comment on
-
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.Arthritis Res Ther. 2010;12(2):R48. doi: 10.1186/ar2959. Epub 2010 Mar 19. Arthritis Res Ther. 2010. PMID: 20302641 Free PMC article.
Similar articles
-
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.Arthritis Res Ther. 2010;12(2):R48. doi: 10.1186/ar2959. Epub 2010 Mar 19. Arthritis Res Ther. 2010. PMID: 20302641 Free PMC article.
-
Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.Ann Rheum Dis. 2009 Jun;68(6):997-1002. doi: 10.1136/ard.2008.090928. Epub 2008 Aug 2. Ann Rheum Dis. 2009. PMID: 18676986
-
Targeting the BLyS-APRIL signaling pathway in SLE.Clin Immunol. 2013 Sep;148(3):322-7. doi: 10.1016/j.clim.2012.11.010. Epub 2012 Dec 6. Clin Immunol. 2013. PMID: 23269199 Review.
-
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.Arthritis Res Ther. 2006;8(6):R167. doi: 10.1186/ar2076. Arthritis Res Ther. 2006. PMID: 17092341 Free PMC article. Clinical Trial.
-
Anticytokine therapy impacting on B cells in autoimmune diseases.Curr Opin Rheumatol. 2009 May;21(3):205-10. doi: 10.1097/BOR.0b013e32832a0760. Curr Opin Rheumatol. 2009. PMID: 19346949 Review.
Cited by
-
Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.Curr Opin Rheumatol. 2011 May;23(3):305-10. doi: 10.1097/BOR.0b013e328344c15e. Curr Opin Rheumatol. 2011. PMID: 21330926 Free PMC article. Review.
-
The Dawn of a New Era of Therapies in Systemic Lupus Erythematosus.Rheumatol Immunol Res. 2020 Dec 1;1(1):31-37. doi: 10.2478/rir-2020-0005. eCollection 2020 Dec. Rheumatol Immunol Res. 2020. PMID: 36465076 Free PMC article.
-
Towards new avenues in the management of lupus glomerulonephritis.Nat Rev Rheumatol. 2016 Apr;12(4):221-34. doi: 10.1038/nrrheum.2015.174. Epub 2016 Jan 5. Nat Rev Rheumatol. 2016. PMID: 26729459 Review.
-
Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus.Life (Basel). 2023 Jul 1;13(7):1496. doi: 10.3390/life13071496. Life (Basel). 2023. PMID: 37511872 Free PMC article. Review.
-
Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.Rheumatol Int. 2014 Sep;34(9):1217-23. doi: 10.1007/s00296-014-3020-4. Epub 2014 Apr 21. Rheumatol Int. 2014. PMID: 24748505
References
-
- Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'era M, Gross JA. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010;12:R48. doi: 10.1186/ar2959. - DOI - PMC - PubMed
-
- Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone T-S. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol. 2002;169:4314–4321. - PubMed
-
- Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995–999. doi: 10.1038/35010115. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous